ICCM
IceCure Medical Ltd.
NASDAQ · Healthcare · Medical - Devices · IL
$1.08
+1.89%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.09
From 52W high−95.80%
Volume146930.00
Market cap$3.70M
P/E (TTM)—
P/S (TTM)0.9x
Div yield—
Key dataOct 19, 2026
Open
$1.09
From 52W high
−95.80%
Volume
146930.00
Market cap
$3.70M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.5x
P/E (TTM)
—
RSI (14)
21.0
MomentumView details →
1D Return
+1.89%
YTD Return
−94.04%
SummaryUpdated Jun 1, 2026
IceCure Medical Ltd (NASDAQ:ICCM) is an Israeli medical device company founded in 2006 and headquartered in Caesarea, Israel. The company went public on NASDAQ in August 2021. IceCure specializes in developing and commercializing cryoablation technology, which uses extreme cold to destroy diseased tissue, particularly for cancer treatment. The company's flagship product, the ProSense system, is designed to treat breast tumors through minimally invasive cryoablation procedures. IceCure is currently awaiting FDA approval for its ProSense system in the United States while maintaining commercial operations in international markets.
Similar companies
Latest newsMore news →
IceCure Medical added Legacy Health in Portland, Oregon, including its Legacy Medical Group–Surgical Oncology at Good Samaritan Medical Center, as a new U.S. clinical site for its post-marketing ChoICE Study evaluating ProSense cryoablation in low-risk breast cancer.14d agoIceCure Medical received regulatory approval to market its ProSense cryoablation system in China.40d agoIceCure Medical entered into an exclusive distribution agreement with Scovas Medical for the distribution of its ProSense cryoablation systems in the Netherlands for breast cancer and interventional oncology.57d ago